학술논문
BIO‐AST Biologics for chronic severe asthma: a network meta‐analysis
Document Type
Author
Source
This record should be cited as: Crossingham, Iain, Crossingham, Iain, CD015411-cr-0003, Crossingham, Iain, Richardson, Rebekah, Hinks, Timothy SC, Spencer, Sally, Couillard, Simon, Maynard-Paquette, Anne-Catherine, Thomassen, Doranne, Howell, Imran. BIO‐AST Biologics for chronic severe asthma: a network meta‐analysis. (Protocol) Cochrane Database of Systematic Reviews 2022, Issue 10. Art. No.: CD015411. DOI: 10.1002/14651858.CD015411.
Subject
Language
ISSN
1465-1858
Abstract
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of biological agents targeting type‐2 inflammation (benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab, tezepelumab) in people with severe asthma, with a network meta‐analysis and to rank agents by effectiveness.